Biopharma is facing compressive disruption that could impact traditional approaches. Find out how New Science can reshape the biopharma landscape and patient care. Visit http://www.accenture.com/newscience to learn more.
The Accenture Life Sciences practice helps companies pivot to the patient for best outcomes. See how we can help you. Visit https://accntu.re/2l5mUGu to learn more.
Governing Innovation: The recipe for portfolio growth | Accentureaccenture
Accenture reports that with innovation investments increasing, it's critical to invest in growth with an innovation portfolio management strategy. Read more.
Accenture’s Global Operations is transforming the core of how operational services are being delivered. By applying new technologies, partnered with Accenture’s global resources, we are working with clients to help them achieve their R&D goals faster, cheaper, better. Visit https://accntu.re/30wesTV to learn more.
The Accenture Life Sciences practice helps companies pivot to the patient for best outcomes. See how we can help you. Visit https://accntu.re/2l5mUGu to learn more.
Governing Innovation: The recipe for portfolio growth | Accentureaccenture
Accenture reports that with innovation investments increasing, it's critical to invest in growth with an innovation portfolio management strategy. Read more.
Accenture’s Global Operations is transforming the core of how operational services are being delivered. By applying new technologies, partnered with Accenture’s global resources, we are working with clients to help them achieve their R&D goals faster, cheaper, better. Visit https://accntu.re/30wesTV to learn more.
Accenture's Technology Vision 2021 details emerging technology trends that will help companies get back on track & build their future post COVID-19. Read more.
Accenture Digital Health Technology Vision 2018accenture
Explore Accenture's Digital Health Tech Vision 2018 report, showcasing five health IT trends that are going to redefine how intelligent enterprises of the future will work. Learn more: https://accntu.re/2IoOLMI
Accenture's six-country survey among 180 C-level health executives says adoption of AI is measured, but real.
The survey assessed beliefs about market maturity, practical and clinical challenges to the adoption of AI in healthcare.
Enthusiasm for AI (artificial intelligence) is high among health executives, with people skills the most important implementation success factor.
Sufficient staff training/ expertise is rated the most important success factors for AI implementation (ranked in top three by 73 percent of execs).
Visit https://accntu.re/2T4KuXb to learn more.
Reinventing the Last Mile: Win the Race to the Top (AU)accenture
A pivotal moment has arrived for traditional postal organisations. As retailers race to the top to win customer loyalty and market share, they are transforming their supply chains to enable the fast and free shipping that customers not only want, but expect. However, traditional postal organisations have not responded accordingly, and are now putting their future survival at risk. But by joining the race to the top—and taking advantage of their enviable position to offer the solutions retailers are looking for—they can transform their networks and win the last mile for decades to come.
AI - The Next Frontier for Connected Pharmasambiswal
Big pharma has long been challenged with siloed data resulting from drug discovery information, clinical trial results and product marketing research stored separately in decade-old legacy systems. Thus, the pharmaceutical industry is ripe for the actionable insights offered by these advances to offset the growing costs of drug discovery while still meeting the demands of a value-based care model. It is time for a connected approach in the pharmaceutical industry.
Accenture's Technology Vision 2021 details emerging technology trends that will help companies get back on track & build their future post COVID-19. Read more.
Accenture Digital Health Technology Vision 2018accenture
Explore Accenture's Digital Health Tech Vision 2018 report, showcasing five health IT trends that are going to redefine how intelligent enterprises of the future will work. Learn more: https://accntu.re/2IoOLMI
Accenture's six-country survey among 180 C-level health executives says adoption of AI is measured, but real.
The survey assessed beliefs about market maturity, practical and clinical challenges to the adoption of AI in healthcare.
Enthusiasm for AI (artificial intelligence) is high among health executives, with people skills the most important implementation success factor.
Sufficient staff training/ expertise is rated the most important success factors for AI implementation (ranked in top three by 73 percent of execs).
Visit https://accntu.re/2T4KuXb to learn more.
Reinventing the Last Mile: Win the Race to the Top (AU)accenture
A pivotal moment has arrived for traditional postal organisations. As retailers race to the top to win customer loyalty and market share, they are transforming their supply chains to enable the fast and free shipping that customers not only want, but expect. However, traditional postal organisations have not responded accordingly, and are now putting their future survival at risk. But by joining the race to the top—and taking advantage of their enviable position to offer the solutions retailers are looking for—they can transform their networks and win the last mile for decades to come.
AI - The Next Frontier for Connected Pharmasambiswal
Big pharma has long been challenged with siloed data resulting from drug discovery information, clinical trial results and product marketing research stored separately in decade-old legacy systems. Thus, the pharmaceutical industry is ripe for the actionable insights offered by these advances to offset the growing costs of drug discovery while still meeting the demands of a value-based care model. It is time for a connected approach in the pharmaceutical industry.
Opportunity analysis of life science tools market in India - A srinivas sash...Srinivas Sashidhar
An analysis of the life science tools market in India and the market opportunity.
Please note this is a proprietary research on my views in a series of srinivas sashidhar's healthcare instinct. Your views and comments are welcome.
I am also open to individual assignments on market consulting in healthcare related markets.
You can follow my blog at https://kchsashi.blogspot.com/
Your cognitive future: How next-gen computing changes the way we live and workIBM in Healthcare
The healthcare industry is undergoing significant change driven by six disruptive forces - rapid digitization, changing consumer expectations, regulatory complexities, increasing healthcare demand, shortage of skilled resources and elevating healthcare costs. To meet the implication of these forces, healthcare organizations must excel in engaging with consumers, discovering new ideas and taking effective decisions
Currently, traditional analytics capabilities are unable to exploit maximum value from the ever increasing data resource constraining organization’s achievements and performance. But cognitive computing has the ability to bridge this gap and can open up fresh opportunities for the healthcare industry. It is already helping healthcare organizations to provide personalized care, effective decisions and more innovative solutions.
Commercial considerations in early drug developmentSunil Ramkali
It is important in the drug development process that marketers and researchers collaborate early to ensure that products being developed are truly innovative and deliver brand value to the different end users in a way that the product and the subsequent brand messaging is relevant, compelling and differentiating compared to the competition. T
In the market place that is heavily cost constraint, innovation is no longer about a unique mode of action or a new formulation, but more about the incremental brand value offered by new pharmaceutical products over existing treatments (standard of care) and how much healthcare systems are prepared to pay for these incremental benefits. My lecture at the Department of Innovation, Lund University, Sweden explored the importance of R&D functions getter closer to external stakeholders to really understand their needs, how they define brand value and the importance of considering this early in the drug development process.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Etude PwC CEO Survey industrie pharmaceutique (2014)PwC France
http://pwc.to/1o06Z5k
Pour cette 17ème édition de l’étude mondiale annuelle de PwC "CEO Survey", 1344 chefs d’entreprise de 68 pays ont été interrogés entre septembre et décembre 2013. 119 dirigeants du secteur pharmaceutique et des sciences de la vie, et 81 dirigeants du secteur de la santé ont participé à l’enquête. Les études complètes sont disponibles sur www.pwc.fr.
Healthcare Industry is considered a defensive industry for investing. It consist of pharmaceuticals, medical device, bio technology and insurance segment.
Historically, the medical device industry has been highly attractive and relatively stable. As a consequence, established players have been able to compete successfully across the device spectrum, applying common business models and processes without much need for differentiation.
The future, however, is very different as disruptive change is underway. Companies will need to look at new segments and offer end-to-end solutions to secure additional revenue and maintain their profit margins.
Similar to New Science: Pharma's new growth machine (20)
Engineering Services: con gli ingegneri per creare valore sostenibileaccenture
Collaboriamo con gli ingegneri di aziende capital intensive per combinare tecnologie innovative con un approccio pragmatico che aiuti a raggiungere risultati aziendali migliori.
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Neuro-symbolic is not enough, we need neuro-*semantic*Frank van Harmelen
Neuro-symbolic (NeSy) AI is on the rise. However, simply machine learning on just any symbolic structure is not sufficient to really harvest the gains of NeSy. These will only be gained when the symbolic structures have an actual semantics. I give an operational definition of semantics as “predictable inference”.
All of this illustrated with link prediction over knowledge graphs, but the argument is general.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Let's dive deeper into the world of ODC! Ricardo Alves (OutSystems) will join us to tell all about the new Data Fabric. After that, Sezen de Bruijn (OutSystems) will get into the details on how to best design a sturdy architecture within ODC.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
"Impact of front-end architecture on development cost", Viktor TurskyiFwdays
I have heard many times that architecture is not important for the front-end. Also, many times I have seen how developers implement features on the front-end just following the standard rules for a framework and think that this is enough to successfully launch the project, and then the project fails. How to prevent this and what approach to choose? I have launched dozens of complex projects and during the talk we will analyze which approaches have worked for me and which have not.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Search and Society: Reimagining Information Access for Radical FuturesBhaskar Mitra
The field of Information retrieval (IR) is currently undergoing a transformative shift, at least partly due to the emerging applications of generative AI to information access. In this talk, we will deliberate on the sociotechnical implications of generative AI for information access. We will argue that there is both a critical necessity and an exciting opportunity for the IR community to re-center our research agendas on societal needs while dismantling the artificial separation between the work on fairness, accountability, transparency, and ethics in IR and the rest of IR research. Instead of adopting a reactionary strategy of trying to mitigate potential social harms from emerging technologies, the community should aim to proactively set the research agenda for the kinds of systems we should build inspired by diverse explicitly stated sociotechnical imaginaries. The sociotechnical imaginaries that underpin the design and development of information access technologies needs to be explicitly articulated, and we need to develop theories of change in context of these diverse perspectives. Our guiding future imaginaries must be informed by other academic fields, such as democratic theory and critical theory, and should be co-developed with social science scholars, legal scholars, civil rights and social justice activists, and artists, among others.
2. 2
The Biopharma industry is facing
compressive disruption,
But a new growth engine is emerging
that will drive the majority of revenue
through 2022.
We call it New Science.
3. 3
WHAT IS
COMPRESSIVE DISRUPTION?
Many asset-heavy organizations
are experiencing a gradual and
dangerous “compressive
disruption” when a series of
innovations, macroeconomic
factors and other changes
combine to squeeze profits
over time.
5. 5
Investor confidence
in future earnings is
declining.
Future Value as a percentage of
Total Enterprise Value has dropped
for three years in a row, from 42%
in 2015 to 28% in 2018.
BIOPHARMA’S
COMPRESSIVE DISRUPTION
01
Sources: Capital IQ. Accenture Research Analysis. Calculations are the aggregated values for the pharmaceutical segment.
Accenture High Performance Business Analysis 2018. Pharmaceutical & Biotechnology relative performance analysis of indicators
including, growth profitability, and value indicators as reported by the market and monitored over 10 years. The HPB study
identifies which companies are top performers within their industry and what distinguished them from their international peers
6. 6
Tenure of market
leading treatments
is declining.
Average tenure for a
market leading treatment
in a therapeutic area has
dropped from 10.5 years in
2001 to 5.1 years in 2017.
BIOPHARMA’S
COMPRESSIVE DISRUPTION
02
Source: Accenture analysis, data provided by Evaluate Pharma
7. 7
BIOPHARMA’S
COMPRESSIVE DISRUPTION
50% decline expected from
2012 thru 2022.
More specialized treatments
coming to market that treat
smaller patient populations
generating lower revenues.
Pipeline replacement
ratios are declining.03
Source: Accenture analysis, data provided by Evaluate Pharma
8. NEW SCIENCE INVOLVES:
A new mechanism, modality, indication or health
technology that has been identified by the FDA or
other regulatory entity as having met an unmet
need, exceeding standard of care
Often has a technology companion
Can be the technology alone
WHAT IS
NEW SCIENCE?
9. 9
NEW SCIENCE WILL DRIVE THE MAJORITY OF
INDUSTRY GROWTH
New Science is expected
to drive 54% of industry
revenue from 2017-2022.
Source: Accenture Research. Capital IQ.
10. 10
NEW SCIENCE IS DRIVING
EXCEPTIONAL GROWTHACROSS MULTIPLE THERAPEUTIC AREAS
Source: Accenture analysis, data provided by Evaluate Pharma
11. 11
NEW SCIENCE IS MORE LIKELY TO
REACH AND PASS
REGULATORY APPROVAL
New Science has a 50%
higher probability of
Technical and Regulatory
Success (PTRS) compared
to other NMEs and NBE’s.
Source: Accenture analysis, data provided by Informa Pharmapremia
12. 12
LEADERS IN
NEW SCIENCE
ARE INVESTING
6-7 X’S AS MUCH IN
DIGITAL, DATA AND GENOMICS
Investments represent convergence of
science and technology rising to meet
demand for proof of improved outcomes.
Source: Accenture analysis